PR View by Melissa Hill

Share this article:
When it comes to life science companies, change can happen overnight. Each morning we wake up to a flurry of headlines affecting the industry, including product failures and setbacks, proposed legislation impacting product exclusivity and new scientific discoveries. While these might be ordinary headlines to most of us, for employees and shareholders involved in these companies, these news events can mean significant change.

With change comes an opportunity for communication and a need for information. As the life science industry matures and companies grow, this presents an even greater challenge in communicating effectively with all key stakeholders. Companies that were once a small group of employees sitting around the boardroom are blossoming into organizations with numerous departments and locations. 

Keeping these employees aware of the company's mission, milestones, achievements and setbacks becomes critical with growth. As life science companies experience change with growth, it provides an ideal time to assess internal and external perceptions. Are employees aware of the company's vision? Are they aware of how the company positions itself to its shareholders? Do they know the plan for the upcoming product approval and launch? 

And equally as important, do external perceptions match internal perceptions? Do shareholders and customers know the direction of the company? Do shareholders know the timeline for your product launch? Make these questions a regular part of your communications plan. Don't be afraid to ask these questions; you might be surprised by what you hear.

As the tide shifts for life science companies, the famous words “knowledge is power” ring true for all of our key stakeholders.

Melissa Hill is VP at Porter Novelli Life Sciences

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...